GSK2018682 is a novel and potent agonist for S1P1 and S1P5 receptor (sphingosine 1 phosphate receptor) with pEC50s of 7.7 and 7.2, respectively, and it has no agonist activity towards human S1P2, S1P3, or S1P4.

YUN88562, formerly known as S1p receptor agonist 1, is an S1P receptor agonist found in patent WO 2015039587 A1, compound example 2.

Pluronic F-68 (P188, Poloxamer 188, MST-188), a non-ionic surfactant and polyol, is a PEO-PPO-PEO polymer (the form polyethylene oxide-polypropylene oxide-polyethylene oxide).

GLPG-2938 is a novel,potent and selective S1P2 antagonist.

CYM-50308 (CYM50308; ML248; ML-248) is a novel and potent agonist of SIP4 (sphingosine-1-phosphate receptor 4) (EC50 = 56 nM).

AM095 sodium is a novel, potent and selective LPA1 receptor antagonist that inhibited GTPγS binding to Chinese hamster ovary (CHO) cell membranes overexpressing recombinant human or mouse LPA1 with IC50 of 0.98 and 0.73 μM, respectively.

Lysophosphatidic acid is an endogenous agonist of the lysophospholipid receptors LPA1 and LPA2, a glycerophospholipid signaling ligand molecule and ligand activator for EDG-2, EDG-4, and EDG-7.

Mocravimod HCl (KRP203) is a novel and potent sphingosine 1-phosphate receptor type 1 agonist, acting as an immunosuppressant that ameliorates atherosclerosis in LDL-R-/- mice.

Amiselimod HCl (formerly also known as MT-1303) is a novel, potent and selective immunosuppressant and sphingosine 1 phosphate receptor (S1P1) modulator.

Ceralifimod (also known as ONO-4641) is a novel sphingosine-1-phosphate (S1P) receptor agonist selective for S1P1 and S1P5.